Table 2.
Dyspnoea: patient-reported incidence and severity.
| Time interval |
Antiplatelet agent |
All dyspnoea n (%) |
Mild n (%) |
Moderate n (%) |
Severe n (%) |
p-value for χ2 |
p-value for linear trend |
|---|---|---|---|---|---|---|---|
| 3 weeks | Ticagrelor n = 116 | 65 (56.0) | 40 (34.5) | 19 (16.4) | 6 (5.2) | 0.040 | 0.11 |
| Clopidogrel n = 63 | 25 (39.7) | 15 (23.8) | 5 (7.9) | 5 (7.9) | |||
| 3 months | Ticagrelor n = 98 | 45 (45.9) | 25 (25.5) | 17 (17.3) | 3 (3.1) | 0.355 | 0.07 |
| Clopidogrel n = 58 | 20 (34.5) | 13 (22.4) | 6 (10.3) | 1 (1.6) | |||
| 6 months | Ticagrelor n = 87 | 36 (41.4) | 21 (24.1) | 11 (12.6) | 4 (4.6) | 0.306 | 0.17 |
| Clopidogrel n = 54 | 16 (29.6) | 8 (14.8) | 7 (13.0) | 1 (1.9) | |||
| 12 months | Ticagrelor n = 83 | 27 (32.5) | 14 (16.9) | 11 (13.3) | 2 (2.4) | 0.846 | 0.39 |
| Clopidogrel n = 55 | 15 (27.3) | 9 (16.4) | 5 (9.1) | 1 (1.8) |